



September 27, 2017

Notice of the Start of Phase 3 Clinical Study of VLP Seasonal Influenza Vaccine

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; President & Representative Director; Masayuki Mitsuka; hereafter, "MTPC") announced today that its affiliated company, Medicago Inc. (Head Office: Quebec, Canada; President & Chief Executive Officer; Bruce D. Clark) has initiated the phase 3 clinical study for its seasonal quadrivalent influenza vaccine candidate. The study is currently taking place in Canada, US, Europe and Asia.

Medicago is the leading biological pharmaceutical company with strengths in R&D for new vaccines using Virus Like Particle (VLP) technology. Medicago has proprietary technologies for the production of VLPs inside plant cells and the efficient extraction and purification of those VLPs. Also, VLPs have the same external structure as viruses, so VLP vaccines are expected to offer a high level of immunization effectiveness.

As the platform utilizes the gene transfer and transient expression technologies, the vaccine production can be initiated with genetic information and the manufacturing period can be remarkably shortened compared with the conventional egg-cultured method.

We are expecting the vaccine to launch in time for the 2020 influenza season in Canada and the US.

MTPC will open up the future of health from the perspective of preventing infectious diseases through vaccine business as in "priority disease areas".

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department

Media contacts: TEL:+81 6 6205 5119

Investor contacts: TEL:+81 6 6205 5110